Xinda Bio (01801.HK) released its interim results with a profit of 834 million yuan in the first half of the year, turning losses into gains year on year.

Wise financial news app, Xinda biotechnology (01801.HK) released its six-month performance ending on June 30, 2025, with the group's revenue from customer contracts reaching 5.953 billion yuan (RMB, same below), a year-on-year increase of 50.6%. The profit for the period was 834 million yuan, turning losses into profits year-on-year, with basic earnings per share of 0.51 yuan.